SCHEMBL31339981

SCHEMBL31339981

Cc1cnc(NC(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1-c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ SORT1 Q99523 1/20 0.43
▸ MAPT P10636 8/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ POLB P06746 1/20 0.42
▸ TRPV1 Q8NER1 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ P2RX1 P51575 1/20 0.41
▸ TMPRSS4 Q9NRS4 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ MCHR1 Q99705 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31339943 0.92 TRPV1 (0.48) ALDH1A1SORT1MAPTTRPV1KMT2A
SCHEMBL31339975 0.91 TRPV1 (0.53) ALDH1A1MAPTTRPV1
SCHEMBL31339978 0.86 BTK (0.48) SORT1TRPV1MCHR1
SCHEMBL31339990 0.85 SORT1 (0.50) SORT1TRPV1P2RX1MCHR1
SCHEMBL31340012 0.84 KDM4E (0.46) ALDH1A1SORT1MAPTNPSR1TRPV1
SCHEMBL31339996 0.83 CLK1 (0.47) MAPT
SCHEMBL31339954 0.83 VNN1 (0.45) SORT1MAPTTRPV1TMPRSS4MCHR1
SCHEMBL31339994 0.82 TRPV1 (0.46) SORT1TRPV1MCHR1
SCHEMBL31340004 0.82 PIN1 (0.46) ALDH1A1MAPTPOLBKMT2ASMN1; SMN2
SCHEMBL31339983 0.81 PIK3CA (0.51) MAPTNPSR1POLBKMT2AP2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF JILIN UNIVERSITY (CN) 2026-05-07 — — US disclosed
EP-4725485-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF Jilin University (CN) 2026-04-15 — — EP disclosed
CN-119285557-A CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof 吉林大学 2025-01-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF GZMB, CD74, GSDMD ALDH1A1 3962/4885SORT1 4391/4885MAPT 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback